CogstateCOGZF 90 Net Margin % is 17.59% as of Dec. 2025, which is 90% above its 10-year median of 9.26. GuruFocus rates COGZF with a GF Score™ of 90/100 and a GF Value™ of $1.57 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Cogstate ranks better than 93.41% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Cogstate's Net Income for the
six
months ended in Dec. 2025 was $4.54 Mil. Cogstate's Revenue for the
six
months ended in Dec. 2025 was $25.78 Mil. Therefore, Cogstate's net margin for the quarter that ended in Dec. 2025 was 17.59%.
The historical rank and industry rank for Cogstate's Net Margin % or its related term are showing as below:
COGZF'
s Net Margin % Range Over the Past 10 Years
Min: -11.43 Med: 9.26 Max: 20.15
Current: 20.15
COGZF's Net Margin % is ranked better than 93.41% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 2.885
vs COGZF: 20.15
Cogstate (OTCPK:COGZF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cogstate Net Margin % Related Terms
Cogstate Net Margin % Historical Data
* Premium members only.
The historical data trend for Cogstate's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Cogstate's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogstate Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cogstate's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogstate (COGZF) has a Net Margin % of 17.59% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Cogstate and its competitors. This is 90% above median its historical median of 9.26. According to the industry distribution chart, Cogstate ranks #44 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 6.6%.
Is Cogstate's Net Margin % too high?
Cogstate's current Net Margin % of 17.59% is 90% above median its 10-year median of 9.26. The Healthcare Providers & Services industry median Net Margin % is 2.89. Cogstate's value of 17.59% is 509.7% above this industry median. Based on the distribution chart, Cogstate ranks #44 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cogstate has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's Net Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cogstate ranks #44 out of 668 companies for Net Margin %. This places Cogstate in the top 7% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.89. Cogstate's value of 17.59% is 509.7% above this benchmark. While the company's 10-year median is 9.26 vs. the industry median of 2.89, Cogstate has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogstate's current Net Margin % of 17.59% is 509.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cogstate and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogstate's current Net Margin % is 17.59%, which is 90% above median its own 10-year median of 9.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (COGZF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.57, compared to a current price of $1.89 — trading 20.4% above its estimated fair value. The current Net Margin % is 17.59%, which is 90% above median its 10-year median of 9.26 and 509.7% above the Healthcare Providers & Services industry median of 2.89. Cogstate's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cogstate (COGZF), the current Net Margin % is 17.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cogstate (COGZF) Overvalued in 2026?
Based on GuruFocus' analysis, Cogstate stock appears to be overvalued.
The current stock price of $1.89 is trading 20.4% above its estimated GF Value™ of $1.57.
GuruFocus considers Cogstate to be Modestly Overvalued.
Key valuation signals for COGZF:
Net Margin %: 17.59% (90% above median its 10-year median of 9.26)
GF Value™: $1.57 vs. price of $1.89 (20.4% above fair value)
Industry Position: 509.7% above the Healthcare Providers & Services median (#44 of 668)
No single metric tells the full story. See the COGZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
90GF Score
Get the complete analysis for COGZF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGZF has been successfully added to your 
